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Dear Colleague: 
I hope you heard the good news that our former Director, RADM Kenneth G. Castro, MD, was 
chosen to receive the Lifetime Achievement Award by the North America Region (NAR) of the 
International Union Against Tuberculosis and Lung Disease (IUATLD). He received this 
prestigious award at the IUATLD NAR annual meeting in February. Please see the article 
about the award in this issue. 
We have initiated the search for a new Director of the Division of Tuberculosis Elimination 
(DTBE) to replace Dr. Castro. As you know, these high-level searches are lengthy and we do 
not expect to have an announcement of a new DTBE Director any time soon. In the interim, I 
continue to serve as acting Director, DTBE, and the other acting assignments remain in place 
as well: Kathryn Koski is acting Deputy Director, John Jereb is acting Associate Director for 
Science, and Lee Ann Ramsey is acting Associate Director for Management and Operations. 
We in DTBE were very sorry to learn of the deaths of two former colleagues, Dr. Charles P. 
Felton and Gus Caras. Both passed away in January 2014. Please read about their lives and 
contributions in this issue. 
We are anticipating introduction of TB elimination reauthorization language in the House. This 
bill will provide authority for agencies involved in TB elimination. If passed and signed by the 
President, this would become the next TB Elimination Act, a public law, which gives federal 
agencies their blueprint for activities and permission to appropriators to fund the programs. 
We are cautiously optimistic about the news of a possible slight budget increase in funding for 
TB activities. It appears that DTBE will have some of its previous funding restored, based on 
the information received to date, although the anticipated level is still below that of fiscal year 
2012. 
The topic of TB drug shortages was the focus of two events in January: the TB Task Force 
update, which met by conference call on January 17; and a meeting held in Washington, DC, 
on January 15. This meeting was convened by the National TB Controllers Association 
(NTCA), PATH, and the Treatment Action Group (TAG). Dr. Ken Castro and I participated by 
telephone; Dr. Sundari Mase and Glen Christie of DTBE’s Field Services and Evaluation 
Branch (FSEB) attended in person. This meeting was also attended by Food and Drug 
Administration (FDA) staff and other interested stakeholders. We have an article about the 
meeting in this issue.  
World TB Day is observed annually on March 24 to commemorate Dr. Robert Koch’s 
announcement that he had determined the causative agent of TB: the M. tuberculosis 
bacterium. After discussions with DTBE staff and partners, “Find TB. Treat TB. Working 
together to eliminate TB” was selected as the theme for World TB Day 2014 in the United 
States. This theme was selected to encourage officials in local and state TB programs to reach 
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out to their communities to raise awareness about TB. It calls for everyone involved in TB 
control to further collaborate to find and treat TB disease and latent TB infection, focusing on 
TB elimination. This theme differed slightly from the Global Stop TB Partnership theme of 
“TB—Reach the 3 Million. Find. Treat. Cure TB.”  A U.S.-specific theme was selected to better 
reflect the TB efforts in our country. 
Many of you sent us your brief descriptions of these activities. Please go to the DTBE World 





      Philip LoBue, MD, FACP, FCCP 
      Acting Director 
      Division of Tuberculosis Elimination 
      National Center for HIV/AIDS, Viral Hepatitis, STD, 
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HIGHLIGHTS FROM STATE AND 
LOCAL PROGRAMS 
 
Second Annual NYC World TB Day Walk 
The New York City Department of Health and Mental 
Hygiene (NYC DOHMH) co-sponsored the 2nd 
Annual New York City World TB Day Walk on 
Saturday, March 22, 2014. They collaborated in this 
event with a strong coalition of TB stakeholders: 
 
• American Lung Association  
• National TB Controllers Association   
• New Jersey Medical School Global TB Institute 
• New York State Department of Health  
• New York City Department of Homeless Services   
• Plaza del Sol Family Health Center 
• RESULTS  
• Treatment Action Group 
 
The theme for this year’s walk was One World. Zero 
TB. The goals of the walk were to (1) raise TB 
awareness among community leaders, local 
politicians, and the general NYC community, (2) 
highlight the experiences of TB survivors and patient 
advocates, and (3) advocate for TB prevention and 
control efforts, both locally and globally. 
The walk started at Union Square and ended at 
Judson Memorial Church, an iconic location known 
for its commitment to social justice. We were honored 
to have opening remarks from Dr. Lee Reichman 
about TB epidemiology, as well as testimonies from 
TB patient survivors and advocates. Last year, we 
were honored to have NYC Council Member Eugene 
Mathieu speak at the rally about the importance of TB 
prevention and control efforts in NYC. This year, the 
coalition invited the NYC DOHMH Commissioner of 
Health, as well as local community leaders and 
politicians. The event concluded with a presentation 
on TB advocacy and how community members can 
get involved.  
The NYC World TB Day Walk represents the 
remarkable efforts of numerous TB stakeholders 
throughout the region encompassing New York and 
New Jersey, working in partnership, all of whom are 
committed to raising awareness about TB as a 
significant public health issue. We are pleased to 
have had another successful walk, and we look 
forward to learning about other World TB Day efforts 
throughout the country!  
—Reported by Martha Alexander, MHS, 
and Farah Parvez, MD, MPH 
 NYC Bureau of TB Control 
and Bureau of Correctional Health Services 
 
Congratulations to 
Dr. Kenneth Castro! 
The North American Region (NAR) of the 
International Union Against TB and Lung Disease 
(UNION) is pleased to present the 2014 Lifetime 
Achievement Award to Dr. Kenneth Castro. This 
award is presented to deserving recipients who have 
made a significant contribution in the field of 
tuberculosis over an entire career. The contribution 
may have been in any aspect of TB, including basic 
science, epidemiology, public health, advocacy, 
patient care, education, nursing, and laboratory 
science. Nominees may be working in any position, 
TB 
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organization, or profession. The award is not given 
on an annual basis, but rather when an individual 
who meets the criteria of the award has come to the 
attention of the organization. Past awardees include 
Dr. Lee Reichman, Dr. Jacques Grosset, Dr. William 
Pape, Dr. Donald Enarsen, Dr. Anne Fanning, Ms. 
Sue Etkind, and Dr. George Comstock. 
Dr. Castro led the Division of Tuberculosis 
Elimination for 20 years, during which time the U.S. 
saw a 63% decline in TB cases. He developed new 
research and program initiatives such as the TB 
Trials Consortium and the TB Epidemiologic Studies 
Consortium, the National Tuberculosis Indicators 
Project, and the National Genotyping Service, as well 
as the Molecular Detection of Drug Resistance 
service. Internationally, Dr. Castro is a founding 
member of the STOP TB Partnership and serves as 
an expert advisor to the World Health Organization 
(WHO). He has chaired numerous international 
conferences and contributed to the development of 
international guidelines in TB control. Despite this 
busy schedule, Dr. Castro remains accessible and 
approachable, inspiring new scientists and clinicians 
into the field, whether by a word of praise at a poster 
session or by a few words in the hallway. A scientist, 
an advocate, a clinician, a teacher, a leader—Dr. 
Castro is truly an ideal candidate for an award that 
recognizes a life-long passion and dedication to TB 
elimination and the goal of zero deaths from TB.  
Dr. Castro received this award in Boston on February 
28. Congratulations, Dr. Castro! 
—Submitted by Jane Carter, MD 
UNION NAR 
 
Solving the Silent Crisis: 
High-Level Working Meeting to 
Resolve and Prevent Domestic TB 
Drug Shortages 
Introduction 
Progress in eliminating TB as a public health problem 
in the United States is threatened by decreasing 
funding and by increasing problems in accessing life-
saving drugs and diagnostics. A year after Treatment 
Action Group (TAG) and partners first convened a 
broad consultation on January 18, 2013, to discuss 
the U.S. and global TB drug shortage crisis, domestic 
shortages of TB products have persisted and 
possibly worsened. Thus, the National TB Controllers 
Association (NTCA), TAG, and partners determined 
there was a need for a follow-up, high-level meeting 
to find inter-agency solutions to the ongoing crisis of 
supply interruptions of TB drug and diagnostic 
products. 
On January 15, 2014, TAG, NTCA, and PATH 
convened a small working group to explore potential 
solutions for more effectively preventing and 
responding to drug shortages. Included at this 
meeting were representatives from the following 
organizations: 
• CDC, Division of Tuberculosis Elimination 
• FDA, Center for Drug Evaluation and Research 
Drug Shortage Program 
• TAG 
• NTCA 
• Infectious Diseases Society of America (IDSA) 
• American Thoracic Society (ATS) 
• Community Research Advisors Group (CRAG) 
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• Global Drug Facility (GDF) 
• RESULTS 
• Association of State and Territorial Health 
Officers (ASTHO) 
• Biomedical Advanced Research and 
Development Authority (BARDA) 
Of note, the causes of the recent shortages of TB 
drugs and biologics are diverse, and vary based on 
manufacturer and product. This complicates the 
ability to intervene with a single solution. Some 
manufacturers report that compromises in the sterility 
of the production process contributed to the shortage. 
Others indicate that a lack of quality in some of the 
active pharmaceutical ingredients used in the product 
forced shutdown of the production of the product. Still 
others indicate that a higher demand than supply 
resulted in the need to allocate existing supply, 
leading to shortages. However diverse the causes, 
the outcome for TB control is consistent: we are left 
without the tools we rely on to both detect and treat 
infection and disease.   
Findings and recommendations from the discussions  
The group discussed a wide-ranging set of potential 
solutions, examining the merits of each, identifying 
barriers to overcome, and determining next steps. 
Lead interventions focused around the following: 
1. Creating a rotating, vendor-managed inventory 
(VMI) reserve 
A VMI option was agreed to be a good short- to 
medium-term solution for responding to acute 
shortages. Since most individual states lack the 
volume of cases and resources to create functional 
individual stockpiles, it was agreed that a national 
system would be the only realistic solution, and it 
would probably save money by eliminating 
redundancy of efforts. The main challenge 
anticipated is to determine resources, as well as the 
specific criteria under which reserves could be used.  
2. Centralizing procurement 
The group suggested that in the long term, 
centralizing procurement could streamline it for 
programs and facilitate supply predictions for 
manufacturers, and would create pooled demand and 
better communications. At the global level, this 
pooled procurement model is exemplified by GDF, 
and most participants felt that the U.S. should 
attempt to procure through GDF, as well, if regulatory 
hurdles could be overcome, especially because GDF 
is funded primarily via the U.S. Agency for 
International Development (USAID). Even if U.S. 
programs were able to procure drugs through GDF, 
the consensus was that a centralized system for 
managing requests and communicating information 
would still be necessary. This could take the form of a 
hybrid model (one in which procurements were 
national, but payment and distribution were regional) 
or a fully centralized model (in which a U.S.-GDF 
procurement system would be created). The main 
challenges expected are limited resources and a 
location for the system. 
3. Expanding the pool of U.S. suppliers 
Discussions focused on potential mechanisms for 
stimulating the U.S. registration of existing quality-
assured sources of TB products. These included 
potentially receiving fast-track review status 
(following the PEPFAR precedent), waiving or finding 
incentives to counteract user fees, leveraging GDF 
relationships, and providing technical assistance to 
manufacturers to facilitate registration. These options 
are potentially challenged by regulatory inflexibilities 
or difficulties identifying resources to create 
incentives for costly and time-consuming FDA 
registration. 
4. Expanding markets to maintain existing U.S. 
suppliers  
In addition to encouraging the registration of GDF 
manufacturers in the United States, the group 
discussed the potential to encourage current U.S.-
approved manufacturers to supply to GDF and 
benefit from the much larger global market for quality-
assured medicines to which the GDF provides 
access. This larger global market could encourage 
continued manufacturing for existing suppliers 
through increased stability and volume. 
5. Improving communications 
When developing a centralized system or alternative 
solution, the group felt an improved communication 
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infrastructure should also be developed to ensure 
that stakeholders can receive and provide up-to-date 
information about shortages. The GDF system was 
considered an example for adaptation, although it 
was recognized that a U.S.-specific system would be 
needed.  
Next steps  
As a way to extend the discussion and work towards 
implementation of the solution, five concrete steps 
were selected: 
• Create a rotating, vendor-managed inventory 
reserve 
• Centralize procurement 
• Expand the pool of U.S. suppliers 
• Expand markets to maintain existing U.S. 
suppliers 
• Implement cross-cutting approaches 
 
The group agreed that additional meetings would 
probably be necessary to advance progress, detail 
action plans, and bring in important stakeholders who 
were not included in this preliminary meeting (e.g., 
representatives from the pharmaceutical industry). 
Progress on this important work, including decision-
making about the most viable options and success 
towards addressing potential barriers, will be 
provided to TB Notes and posted on the NTCA and 
TAG websites. 
—Submitted by Erica Lessem, TAG 
Donna Hope Wegener, NTCA 
Kenyon Farrow, TAG 
 
NTCA UPDATES 
2014 National TB Conference 
The theme for the 2014 National TB Conference is 
Sharing the Vision of TB Elimination. The National TB 
Conference will be held at the Grand Hyatt Atlanta in 
Buckhead June 11–13, 2014. Following are some 
highlights of this year’s conference: 
• Looking where the light is bad—What’s really 
limiting treatment of latent TB infection? Keynote 
given by Dr. Dick Menzies 
• Joining Dr. Menzies in the opening plenary are 
Drs. Jonathan Mermin (Director, NCHHSTP, 
CDC) and Jenny Flood (NTCA President and CA 
TB Controller), who will outline the vision for TB 
elimination 
• Faculty include staff from state, big city, and 
territorial TB control programs 
• NSTC and NTNC, sections of NTCA, will hold 
educational sessions on June 10 
• Post-conference meetings on June 13 include 
U.S. Mexico Border Summit and Challenges and 
Issues in Ensuring High Quality of TB 
Surveillance Data 
Conference registration information, including 
instructions for submitting abstracts for poster 
presentation, is available on the NTCA website, 
www.tbcontrollers.org.  
Call for 2014 NTCA Awards 
Do you know someone who deserves to be 
recognized by their peers for their leadership, 
professionalism, and commitment to TB control?  
Now is your chance to give them that recognition. 
Nominations for the 2014 NTCA Awards are now 
being accepted. These awards, started in 2010, are 
designed to honor those in the TB community who 
have demonstrated leadership, professionalism, and 
passion for their work in TB control.  The deadline for 
nominations is April 30, 2014.  The form and 
instructions for submitting a nomination are available 
on the NTCA website, www.tbcontrollers.org. 
The NTCA Award categories are as follows: 
• TB Controller of the Year—This is the National 
Tuberculosis Controller’s highest award; what TB 
controllers are all about! It recognizes an 
outstanding contribution and impact on 
tuberculosis prevention and control at the local, 
state, regional, or national level.  
• Carol Pozsik Nursing Award—honors 
exemplary care, service, dedication, or 
leadership in the field of TB nursing.  
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• William Stead Clinician Award—recognizes 
outstanding commitment and performance by a 
clinician providing tuberculosis care, leadership, 
or mentoring.   
• Ed Desmond Award—honors exemplary 
service, dedication, or leadership to a 
tuberculosis laboratory professional.      
• Robert Koch Award—recognizes outstanding 
contributions with a clinical, epidemiological, or 
academic focus by a tuberculosis researcher in 
the quest to eliminate tuberculosis.   
• Dixie Snider Award—recognizes a CDC 
employee who has provided outstanding support, 
through partnership with a state or local 
tuberculosis community, in the interest of 
tuberculosis control and prevention. 
• Charles DeGraw Advocacy Award—recognizes 
an individual or organization that has made an 
outstanding effort or achievement in advocating 
for increased support and recognition of 
tuberculosis control and prevention efforts. 
• Joe Ware Partner Service Award—recognizes 
an organization that has made a significant effort 
and/or contribution to the mission of tuberculosis 
control and prevention through advocacy and 
partner activities.  
NTCA Personnel Changes 
NTCA is pleased to announce the newest member of 
the central office team—Jennifer Kanouse. Jennifer 
was named NTCA’s Director of Communications 
and Member Services, effective January 15, 2014. 
Since 2009, Jennifer has been an important member 
of the NTCA team, serving on a part-time basis as a 
Special Projects Coordinator. Jennifer has an 
instructional design background and was previously a 
member of the Curry International TB Center’s staff. 
She joins a staff of two (Eva Forest and Donna Hope 
Wegener) providing instrumental support to the 
NTCA Board, NTCA committees and workgroups, the 
NTCA membership, and TB control programs.  
—Submitted by Donna Hope Wegener 
NTCA 
TB PROGRAM EVALUATION 
NETWORK UPDATES 
Tools for Teach Back: Medication Safety 
Project 
Background and statement of problem 
Low health literacy is a well-documented problem in 
the United States. Nearly 9 out of 10 U.S. adults have 
difficulty using routine health information; only 12 
percent of English-speaking adults in the United 
States have proficient health literacy skills. Recent 
refugees and immigrants are among the populations 
most likely to experience limited health literacy.1 
Maine detects an average 450 latent M. tuberculosis 
infections annually, of which 80% are in foreign-born 
persons. (Note: while latent TB infection [LTBI] is not 
a nationally reportable condition, some states have 
implemented reporting of LTBI; Maine is among 
these.) In Maine, as in other states, public health 
nurses (PHNs) have the role of educating patients 
about the signs and symptoms associated with 
isoniazid (INH) therapy, i.e., hepatotoxicity. Despite 
these efforts, there is evidence that not all patients 
understand the health risks, thereby compromising 
their LTBI treatment. 
The Public Health Nursing Program and the TB 
Program are in two separate divisions within the 
Maine Center for Disease Control and Prevention. 
However, they work closely together on prevention, 
diagnosis, treatment, and management of LTBI and 
TB disease. 
During 2010–2011, two patients in Maine with LTBI 
were hospitalized for acute INH-associated 
hepatotoxicity; one of the hospitalized patients was 
U.S. born, with a primary language of English. Each 
patient had received Public Health Nursing Program 
services, including, at a minimum, the following: 
• Monthly in-person education (including provision 
of educational materials) about signs and 
symptoms of potential adverse events and steps 
to take if they occur (stop taking medicine and 
contact provider), and 
• Monthly PHN services, which include being 
monitored for adherence to, and tolerance of, the 
prescribed treatment regimen. 
NUMBER 1, 2014 
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Investigation of the first case by the national Centers 
for Disease Control and Prevention (CDC) revealed 
that standard procedures had been followed by all 
public health staff providing TB services to the 
patients. The patients had been informed more than 
once about signs and symptoms of potential adverse 
events of INH, as well as what to do if such events 
occurred: stop taking the INH and call their health 
care providers (PHN or physician). Both patients had 
continued to take INH despite worsening symptoms, 
and neither called a health care provider to report the 
events. CDC investigators who reviewed the two 
illnesses recommended that consideration be given 
to increasing the amount of education and 
information provided to LTBI patients about the signs 
and symptoms of potential adverse events caused by 
INH and the patient’s proper response. 
Methods: pilot-project implementation, April 2012–
April 2013 
In 2011, staff of the Maine TB Program and the 
Public Health Nursing Program planned and 
developed a pilot project to implement the CDC 
recommendations. The main goal of the project was 
to improve the education provided to LTBI patients 
about the risks of INH therapy and actions to take if 
signs and symptoms of an adverse event occurred. 
The TB program contracted with a graphic designer 
and worked with him to develop the images to be 
used in the educational materials. In collaboration 
with the PHNs, images were chosen depicting the 
side effects potentially associated with INH therapy, 
to use on education materials. The PHNs were also 
asked to give their preferences for the items that 
would display the medication safety messages. 
After reviewing all of the LTBI referrals that Maine 
had received the previous year, the team found that 
the majority of individuals listed country of birth as 
Somalia and their preferred language as Somali. For 
this reason, despite the fact that neither of the two 
prior patients with adverse events were Somali, the 
project team chose Somali participants for a focus 
group and chose that additional language for the 
materials. Thus, a focus group of Somali women, 
most of whom spoke Somali and not English, met to 
assist in the development of educational materials 
culturally and linguistically matched to the needs of 
these women and to choose images most 
representative to them of potential adverse events. 
Staff of the TB and PHN programs worked together 
to develop patient education materials that would 
meet the cultural and linguistic needs of LTBI patients 
(8½″ x 11″ tear sheets, pill box cover, calendar, and 
magnet; Figures 1 and 2). These include images of 
signs and symptoms of INH adverse events and 
steps to take if any occur. A written description of 
each image was provided in Somali and English on 
the tear sheet. 
In addition to these materials, the Teach Back 
method was used to improve PHN-patient 
communication. Teach Back is a teaching method in 
which the learner repeats back what he or she heard 
from the instructor to verify correct understanding of 
the information. If what is repeated is inaccurate, the 
messages and the explanations are repeated until 
the learner’s understanding and recall are both 
accurate.  
The team also developed a four-question interview 
form (Figure 3). The interview form, together with the 
Teach Back technique, was designed to capture 
patients’ demonstration of their understanding of the 
name of their LTBI medication, eight potential signs 
and symptoms of adverse events of the medication, 
and what they should do if they experienced any of 
those signs and symptoms. 
Training for the project and the Teach Back method 
was provided for PHNs, both in person and through 
Adobe Connect, in April 2012. (Note: Adobe Connect 
is a web conferencing platform for web meetings, 
eLearning, and webinars.) This marked the start of 
the pilot project. 
During LTBI treatment, a PHN is assigned to every 
high-risk patient, including foreign-born patients, and 
conducts monthly LTBI visits. All new high-risk LTBI 
patients taking INH were eligible to enroll in this 
project. During the project period, on visit #1, the 
PHN was to complete the four-question interview to 
determine the patient’s baseline recall of information 
about INH. The PHN would use the calendar, pill box, 
and Teach Back technique to re-instruct the patient. 
On visit #2, Teach Back was to be used with tear 
sheets to educate on signs and symptoms of adverse 
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events. On visit #3, the PHN would use the same 
four-question interview to assess the patient’s recall 
of signs and symptoms of adverse events and what 
to do if they occur. After each visit, the PHN was 
asked to document that Teach Back was used and to 
fax the interview forms to the TB control staff, and 
also to enter the information into CareFacts™, the 
electronic medical record system used by PHNs. 
For the duration of the project period, the PHNs were 
asked to document that they had provided a specific 
medication safety message to patients using the 
interview form and the Teach Back methodology. 
Several months into the project, PHNs integrated the 
interview form into the electronic medical record 
system, CareFacts™, so that PHNs could fill out the 
electronic interview and not have to fill out and fax 
the paper form. The PHNs were then able to use the 
interview in paper form, electronic form (integrated 
into CareFacts™ after the project was initiated), or 
both to assess the patient’s knowledge and to deliver 
the medication safety message. 
Throughout the project, TB Control and nursing staff 
met routinely to discuss progress and challenges and 
make necessary adjustments. Midway through the 
project, TB control and PHN staff completed a 
preliminary analysis of data from the interview forms 
and surveyed the PHNs. In April 2013, the 1-year 
pilot project was completed and analyzed, and PHNs 
adapted a modified version of the project into their 
LTBI policies. The findings were shared with PHNs 
and providers through presentations at PHN 
Supervisor and TB Cohort Review meetings. 
Analysis and significant findings 
Upon project completion, TB control and nursing 
program staff analyzed three elements: 
• The information from the interview forms, to look 
for change in patient knowledge; 
• Change in documented patient knowledge, 
behavior, and status (KBS) related to LTBI 
medication adverse events; and 
• PHN experience and ideas, via electronic survey 
and informal interviews. 
Analysis of interview forms 
Analysis shows that the goal of delivering the safety 
messages and assessing patient response at the first 
and third PHN visit was partially met. The electronic 
health record reflected that 226 patients had received 
LTBI services by PHN. Of these, 74 patients (33%) 
had first and third visits documented by interview 
form completion. A variety of patient and PHN 
circumstances adversely affected the ability of the 
PHNs to provide first- and third-visit interviews. 
Patients changed place of residence and 
experienced complex health and cultural issues, and 
there were data entry errors. As a result, 152 (67%) 
of the patients eligible to be in the project did not 
have complete data and were therefore unable to be 
analyzed for change in knowledge or behavior related 
to LTBI medication safety. 
Among the 74 patients with both first and third visits 
documented, 17 (23%) were unable to name the 
medication at the first visit, but were able to name it 
at the third visit. Also, 15 (20%) of project patients 
were unable to verbalize any of the eight signs and 
symptoms at their first Teach Back visit, but were 
able to report on an average of three additional signs 
and symptoms by their third visit. Most notably, 61 
(83%) of patients who received a third visit gave the 
desired response that they should first stop their 
medications and then call a PHN or provider if they 
experienced signs and symptoms. No signs and 
symptoms of severe adverse events occurred during 
the project period. 
Analysis of patients’ KBS 
Nursing assessments were documented in each 
patient’s nursing care plan using the Omaha System 
terminology.2 This system provides PHNs with a 
mechanism for describing patient outcomes related to 
their knowledge, behavior, and status (KBS). PHNs 
rated and recorded their patients’ KBS on initial, 
interim, and discharge visits. The KBS ratings 
documented for former patients discharged from the 
PHN project (n=127) and those still being served by 
PHNs (n=44) by project completion were compared 
to initial KBS ratings collected when the patient was 
first enrolled by a PHN. (Note: 45 patients did not 
receive a KBS rating beyond the initial rating, thus 
their data could not be included in and analyzed for 
this project.) Of the 171 patients who received initial 
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and subsequent ratings, both the discharge and last 
rating averages showed improvement when 
compared to average initial KBS ratings. Delivery of 
project services probably contributed to this 
improvement, but was not exclusive of other nursing 
service variables. 
Post-project, the PHN program has elected to 
continue the main components of this project, with 
modifications. Documentation of using Teach Back is 
now exclusively electronic and is required at the first 
PHN visit, but at subsequent visits is left to the 
discretion of the nurse. The PHN program plans 
continued data analysis of project results as part of 
its ongoing quality improvement, strategic planning, 
and performance management activities. 
Analysis of Nursing Survey 
In October 2012, a nine-question electronic survey 
using the tool Survey Monkey was sent to all 50 
PHNs, who were encouraged to participate. Thirty 
(60%) completed the survey. Key findings included 
the following: 
• If the same materials were ordered again, 90% of 
PHNs surveyed would use them. 
• PHNs selected the calendar and tear sheets as 
most useful, and the magnets and pill boxes as 
least useful. 
• In addition to Somali and English, PHNs 
requested the materials be translated into 
additional languages; French was the most 
requested language by PHNs. 
TB control staff had resources to translate the tear 
sheets into one additional language, so French was 
selected. Because of program budget constraints, 
only the tear sheets could be re-ordered, not the 
calendars, magnets, or pill boxes. The health 
department now offers the following language and 
INH medication options for tear sheets: French with 
English and Somali with English. 
Limitations 
• When the interview form became available in 
CareFacts™, and faxing the form was no longer 
a requirement, PHNs did not complete a 
significant number of Visit 3 electronic forms, 
leaving 152 (67%) of patients who were in the 
project with incomplete data. 
• There was some variability among PHNs in skill, 
comfort, and experience with LTBI patients and 
the Teach Back method. 
• It was unknown if PHNs’ personal preferences for 
certain tools introduced bias. 
• There was no control group—all new LTBI 
patients were supposed to be enrolled in the 
project. 
Conclusions 
By increasing some patients’ knowledge about 
recognizing and correctly responding to signs and 
symptoms of INH adverse effects, we were able to 
partially achieve our original project goal. We cannot 
definitively prove a direct causation between this 
project and actual improved patient medication 
safety, because other nursing interventions occurred 
simultaneously. However, PHNs’ use of educational 
tools and the Teach Back technique did increase 
patient recall of signs and symptoms of INH adverse 
events, and actions to take if these occur. 
In addition, KBS analysis showed that patients were 
taking action to improve their health. Most notably, 
there were no severe adverse events related to 
medication toxicity in the project period. This increase 
in patient knowledge and behaviors will ideally 
translate into fewer adverse events, improved 
adherence to LTBI therapy, and higher treatment 
completion rates. Through this and other 
collaborative projects, we aim to achieve a reduction 
in the number of TB cases in Maine, our ultimate and 
long-term goal. 
Recommendations include further analysis of 
• CareFacts™ data 
• Participation levels of each PHN (i.e., what 
percent of each PHN LTBI patients were included 
in both first and third visits) 
• Tools used, and whether PHN or patient choice 
influenced outcome 
• Patient experiences and language preferences
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—Reported by Dalit Wolfe, RN, BSN, MPH, 
Lori Wolanski, MPH, Pamela Correll, MS, RN, 
and Ted Hensley, RN, MSN 








AND BEHAVIORAL STUDIES 
BRANCH UPDATES 
The 12-Dose Regimen for Latent TB 
Infection Patient Education Brochure Is 
Now Available in Spanish 
The Division is pleased to report that the 12-Dose 
Regimen for Latent TB Infection patient education 
brochure has been translated into Spanish and is 
available for download from the CDC website.  
This brochure was developed for clinicians to use 
with patients while discussing the 12-dose regimen 
for the treatment of latent TB infection. The brochure 
contains information on latent TB infection, the 12-
dose regimen, treatment schedules, and adverse 
events. Space is provided to write in treatment 
schedules and clinic/office contact information.  
It is currently available for download in two paper 
sizes. It may be printed on two sheets of letter-sized 
paper (8.5 x 11 inches), or one sheet of ledger-sized 
paper (11 x 17 inches) that can be folded in half to 
create a 4-page brochure. 
To access the brochure on the CDC DTBE website, 
please go to TB Publications and Products: 
Pamphlet, Brochures, Booklets, and click on “The 12-
Dose Regimen for Latent TB Infection-Patient 
Education Brochure.” This link will connect to a page 
dedicated to this brochure, with information provided 




Under the title of the page, the link to the Spanish 
version is on the left side. (Click your mouse on the 
word “Español.”) You can access the Spanish version 
of the webpage directly at 
http://wwwdev.cdc.gov/tb/esp/publications/factsheets/
folleto.htm. 
—Submitted by Joan Mangan, PhD, MST 
Div of TB Elimination 
 
New TB Personal Stories Videos 
Patients’ stories detailing their experiences with TB 
disease and latent TB infection are now available on 
CDC’s TB website as part of the TB Personal Stories 
project, which began in 2013.  The TB Personal 
Stories project supports the goal of raising 
awareness about TB in the United States. Specific 
objectives include communicating the following key 
points: 
• TB still exists, and it poses serious health 
consequences if not controlled; 
• Real people still get TB every day and have been 
helped with treatment; and 
• Most importantly, public health provides the 
critical support that TB patients need in order to 
be diagnosed and cured of TB. 
Four videos are available. The longest video, TB 
Personal Stories, is a compilation that includes 
commentary from Dr. Kenneth Castro, former 
Director of the Division of Tuberculosis Elimination, 
as well as interviews 
with three TB 
patients.  
Another video 
available is from a 
former patient named 
Santos. Santos first 
heard about TB when his infant son became ill and 
was diagnosed with TB meningitis. Santos then 
learned that he himself had latent TB infection. He 
started treatment for latent TB infection, but didn’t 
finish it. Years later, he came down with TB disease. 
Santos now serves as a peer counselor at his county 
health department for other people who have latent 
TB infection. Learn more about his story here. 
Deo's story, which 
relates his reactions to 
being diagnosed with 
latent TB infection, is 
also available on video. 
Deo was born in Bhutan 
and worked as a medical 
professional before 
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moving to the United States. A health screening 
when he arrived in the country revealed he had latent 
TB infection. Learn 
more about his 
story here. 
Tri’s experience 
with TB disease is 
detailed in his 
video. Tri found 
out he had TB 
shortly after 
beginning college. After 9 months of treatment for TB 
disease, Tri is back doing what he loves—playing 
basketball. Learn more about his story here. 
We are hoping to add additional stories from TB 
patients, so if you know of a former or current TB 
patient who you think would be a good fit for this 
project, please ask him or her to contact Nicole 
Richardson-Smith at ewo0@cdc.gov or Ann Lanner 
at lah1@cdc.gov. The ideal candidate would be an 
adult (18 or over) patient who 
• Was successfully detected, treated, and cured of 
TB; 
• Would be willing to appear in a print or video 
story that could be seen by many people; and 
• Would be a good candidate for videotaping—
articulate and with a compelling story to tell. 
—Reported by Nicole Richardson-Smith, MA 
and Ann Lanner  
Div of TB Elimination 
 
INTERNATIONAL RESEARCH AND 
PROGRAMS BRANCH UPDATES 
IRPB Biennial Report 2011–2012 
The mission of DTBE’s International Research and 
Programs Branch (IRPB) is to contribute to the 
reduction of TB prevalence and mortality globally, as 
well as among foreign-born persons in the United 
States. Activities are carried out through partnerships 
with other U.S. government (USG) agencies and 
various international agencies and groups. 
A number of IRPB’s significant accomplishments 
from 2011 through 2012 have been highlighted in its 
Biennial Report. These achievements were made 
possible through collaboration with and extensive 
support from our USG partner agencies and our 
partner governments’ TB programs, TB laboratories, 
and HIV/AIDS control programs. The Biennial Report 
includes a compilation of select accomplishments 
and proposed activities which embody IRPB’s 
mission and focus 
areas. Please access 






—Reported by Kawi Mailutha, MPA 




Southeastern Mycobacteria Meeting 
Members of the Applied Research Team from 
DTBE’s Laboratory Branch participated in the 5th 
Southeastern Mycobacteria Meeting in Birmingham, 
Alabama, January 24–26, 2014. This conference is 
designed to showcase current research, build 
relationships, and foster collaborations among 
attendees. 
The Applied Research Team presented seven 
posters, three of which focused on the team’s current 
work aimed at improving the detection of 
pyrazinamide (PZA) resistance. PZA resistance is 
problematic for growth-based assays. Alexandra 
Mercante described a modified protocol for 
determining PZA resistance via the widely used 
MGIT system. This protocol uses a reduced inoculum 
size, leading to a decrease in false resistance. Kristin 
Birkness presented data describing development of a 
colorimetric assay in E. coli for detection of the 
effects of mutations in pncA, the gene which encodes 
pyrazinamidase (PZase) activity and can predict 
resistance to PZA. The assay was applied to 88 
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isolates with pncA mutations. Prediction of resistance 
based on PZase activity as determined in the E. coli 
assay correlated well with MGIT results. The Applied 
Research Team’s ongoing effort to construct over 
1,000 mutations in pncA and assess these mutations 
in the previously described E. coli assay was detailed 
on Kelsey Hughes’ poster. The team has thus far 
completed construction and evaluation of 121 pncA 
mutations, observing highly reduced levels of PZase 
activity in a number of the mutations assessed.   
The Ion Torrent Personal Genome Machine (PGM) 
can generate up to 6 million bases of sequence data 
from as many as 96 individual samples in about 2 
hours. Melisa Willby’s poster presented the team’s 
efforts to simplify large-scale drug-resistance 
surveillance efforts through development of a 
multiplexed assay for detecting mutations associated 
with drug resistance. In initial experiments comparing 
Ion Torrent results with traditional sequencing, the 
Ion Torrent Suite software did not find all expected 
mutations. However, when the data were examined 
directly by the investigators, all expected mutations 
were found. This highlighted the need for 
improvements in the current sequence analysis 
software programs. These experiments also 
emphasized the need for a more streamlined 
approach to sample preparation. The poster 
described preliminary efforts to improve efficiency 
and decrease cost. 
Spoligotyping is an assay used to genotype M. 
tuberculosis strains. Paige Gupton presented results 
of a pilot study in which the M. tuberculosis 
spoligotyping assay was transferred from the 
currently used Luminex platform to the Ion Torrent 
PGM. Using the Ion Torrent assay, 270 previously 
spoligotyped samples were reanalyzed, with a 
resulting 100% concordance between the two 
platforms.  The Applied Research Team began 
spoligotyping on the Ion Torrent in October 2013 for 
routine surveillance. 
Improved vaccination strategies against TB are 
urgently needed, for example, approaches to boost 
immune responses induced by the current vaccine, 
BCG. Design of these strategies has been hampered 
by a lack of knowledge of the kinetics of the host 
immune responses induced by BCG vaccination. 
Subhadra Nandakumar described longitudinal 
changes in the effector functional abilities of BCG 
vaccination induced T-cells and their association with 
the protection against M. tuberculosis over a period 
of 2 years in the mouse model. Her presentation 
highlighted the lifelong BCG persistence and its 
association with the attrition and exhaustion of T-cell 
response and waning of protective efficacy against 
M. tuberculosis in mice. Her results questioned the 
empirical development of BCG-booster vaccines and 
emphasized the pursuit of strategies that maintain 
superior T-cell functional capacity. 
Expanding on this topic, Suraj Sable presented 
prime-boost vaccination strategies using BCG and an 
effective subunit vaccine based on the adhesin, Apa. 
His presentation described the ability of Apa subunit 
vaccine to boost waning BCG immunity in older mice 
regardless of its native or recombinant form. These 
results have implications for the development of 
effective prime-boost vaccination strategies against 
tuberculosis. 
The posters and talks presented by other attendees 
provided an important glimpse into the state of 
current research in the mycobacteria field. 
Additionally, this conference provided a valuable 
forum for not only sharing our current research with 
the mycobacterial community, but also for discussing 
future directions and possible collaborations. As we 
pursue a greater understanding of M. tuberculosis 
from these and other activities, we hope to be part of 
achieving the U.S. goal of TB elimination. 
—Submitted by Melisa Willby, PhD, 
and Suraj Sable, DVM, PhD, 
Div of TB Elimination 
 
SURVEILLANCE, EPIDEMIOLOGY, 
AND OUTBREAK INVESTIGATION 
BRANCH UPDATES 
Report on the DTBE Homeless Work 
Group 
 
As TB incidence decreases in the United States, 
focus has turned toward populations at high risk for 
exposure to M. tuberculosis and for progression to 
TB disease. One important group includes persons 
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experiencing homelessness. In the United States, the 
condition of being homeless within 12 months of TB 
diagnosis is reported in about 6% of TB cases. The 
common use of congregate settings such as shelters 
increases the possibility of exposure to TB. This 
population has high TB case rates relative to the 
general population—homeless people have a 10-fold 
higher risk of TB than the general population. In 
addition, homeless persons have higher rates of HIV 
infection, substance use, and mental illness than the 
general population, thereby increasing their likelihood 
of progressing to TB disease. 
 
Over the last decade, CDC has been involved in 
helping to investigate and control numerous TB 
outbreaks involving homeless persons. These recent 
investigations have demonstrated that outbreaks 
including TB patients who are homeless involve large 
numbers of persons (both secondary cases and 
contacts), relative to those outbreaks not including 
homeless patients. Despite the recognized risk of TB 
among persons experiencing homelessness, few 
evidence-based TB control practices are directed 
toward interruption of M. tuberculosis transmission in 
this population. 
 
To help address these issues, DTBE has convened a 
work group to address TB among persons 
experiencing homelessness. The mission of the 
DTBE Homeless Work Group (HWG) is to facilitate 
the prevention, control, and elimination of TB among 
persons experiencing homelessness. 
 
One of the first activities of the HWG was to assist in 
coordination of a meeting regarding TB control with 
other federal and non-profit agencies that work 
addressing housing and healthcare in persons 
experiencing homelessness. The U.S. Interagency 
Council on Homelessness hosted the meeting. In 
attendance were representatives of the departments 
of Housing and Urban Development, Health and 
Human Services, and Veterans Affairs, the 
Substance Abuse and Mental Health Services 
Agency, the National Health Care for the Homeless 
Council, the National TB Controllers Association, 
Stop TB, the National Alliance to End Homelessness, 
and the National HIV/AIDS Housing Coalition, among 
others. Drs. John Bernardo and Sapna Morris 
presented information regarding TB infection and 
disease, and how TB affects persons experiencing 
homelessness. The information was well received, 
and many of the attendees acknowledged that their 
grantees may not be aware of the potential problems 
that TB disease or infection could present for their 
agencies or the risk of transmission that could occur 
if a patient were to go undiagnosed. 
 
Plans have been made for DTBE and local TB 
programs to provide educational messages to these 
federal and non-profit partner agencies on TB 
infection, TB disease, and infection control measures 
(or measures to reduce transmission). In addition, 
these partner agencies are enthusiastic about 
sharing educational messages on housing, 
substance use treatment, and advocacy for persons 
experiencing homelessness with TB control 
programs. 
 
—Reported by Sapna Bamrah Morris, MD 
Div of TB Elimination 
 
 
NEW CDC PUBLICATIONS 
 
Baker BJ, Moonan PK. Characterizing tuberculosis 
genotype clusters along the United States-Mexico 
border. [Short communication.] The International 
Journal of Tuberculosis and Lung Disease 2014 
March 1; 18 (3): 289-291. 
 
Bamrah S, Desmond E, Ghosh S, France AM, 
Kammerer JS, Cowan LS, Heetderks A, Forbes A, 
Moonan PK. Molecular Epidemiology of 
Mycobacterium tuberculosis in the United States-




Borchert JN, Tappero JW, Downing R, Shoemaker T, 
Behumbiize P, Aceng J, Makumbi I, Dahlke M, Jarrar 
B, Lozano B, Kasozi S, Austin M, Phillippe D, Watson 
ID, Evans TJ, Stotish T, Dowell SF, Iademarco MF, 
Ransom R, Balajee A, Becknell K, Beauvais D, 
Wuhib T. Rapidly building global health security 
capacity - Uganda demonstration project, 2013. 
MMWR 2014 Jan 31;63(4):73-6. 
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Cruz AT, Starke JR, Lobato MN. Old and new 
approaches to diagnosing and treating latent 
tuberculosis in children in low-incidence countries. 
Curr Opin Pediatr 2013 Dec 2. [Epub ahead of print.] 
 
Dorman SE, Belknap R, Graviss EA, Reves R, 
Schluger N, Weinfurter P, Wang Y, Cronin W, Hirsch-
Moverman Y, Teeter LD, Parker M, Garrett DO, 
Daley CL. Interferon-γ release assays and tuberculin 
skin testing for diagnosis of latent tuberculosis 
infection in healthcare workers in the United States. 
American Journal of Respiratory and Critical Care 
Medicine 2014; 189 (1): 77-87. doi: 
10.1164/rccm.201302-0365OC  
 
Mitruka K, Blake H, Ricks P, Miramontes R, Bamrah 
S, Chee C, Hickstein L. A tuberculosis outbreak 
fueled by cross-border travel and illicit substances: 
Nevada and Arizona. Public Health Reports 2014 
Jan-Feb; 129:78-85. 
 
Mortensen E, Hellinger W, Keller C, Cowan LS, Shaw 
T, Hwang S, Pegues D, Ahmedov S, Salfinger M, 
Bower WA. Three cases of donor-derived pulmonary 
tuberculosis in lung transplant recipients and review 
of 12 previously reported cases: opportunities for 
early diagnosis and prevention. Transpl Infect Dis 
2014. Article first published online 2014 Jan. 3. DOI: 
10.1111/tid.12171. 
 
Pang J, Teeter LD, Katz DJ, Davidow AL, Miranda W, 
Wall K, Ghosh S, Stein-Hart T, Restrepo BI, Reves 
R, Graviss EA; on behalf of the Tuberculosis 
Epidemiologic Studies Consortium.  Epidemiology of 
Tuberculosis in Young Children in the United States. 
Pediatrics 2014 Feb 10. [Epub ahead of print.] 
 
Shah NS, Yuen CM, Heo M, Tolman AW, Becerra 
MC. Yield of contact investigations in households of 
patients with drug-resistant tuberculosis: systematic 
review and meta-analysis. Clin Infect Dis 2014; 58 
(3): 381-391. doi:10.1093/cid/cit643. 
 
Shea KM, Kammerer JS, Winston CA, Navin TR, 
Horsburgh CR Jr. Estimated rate of reactivation of 
latent tuberculosis infection in the United States, 
overall and by population subgroup. Am J Epidemiol 
2014 Jan 15;179(2):216-25. doi: 10.1093/aje/kwt246. 
 
Tran PD, Vu LN, Nguyen HT, Phan LT, Lowe W, 
McConnell MS, Iademarco MF, Partridge JM, Kile JC, 
Do T, Nadol PJ, Bui H, Vu D, Bond K, Nelson DB, 
Anderson L, Hunt KV, Smith N, Giannone P, Klena J, 
Beauvais D, Becknell K, Tappero JW, Dowell SF, 
Rzeszotarski P, Chu M, Kinkade C. Strengthening 
global health security capacity - Vietnam 
demonstration project, 2013. MMWR 2014 Jan 
31;63(4):77-80. 
 
Walter ND, Painter J, Parker M, Lowenthal P, Flood 
J, Fu Y, Asis R, Reves R. Persistent latent 
tuberculosis reactivation risk in United States 
immigrants. AJRCCM 2014; 189 (1): 88-95. 
 
Weiner M, Egelund EF, Engle M, Kiser M, Prihoda 
TJ, Gelfond JAL, William Mac Kenzie WM and 
Peloquin CA. Pharmacokinetic interaction of 
rifapentine and raltegravir in healthy volunteers. J 
Antimicrob Chemother 2014; published ahead of print 
Dec 2013. doi:10.1093/jac/dkt483. 
 
Whitworth WC, Goodwin DJ, Racster L, West KB, 
Chuke SO, Daniels LJ, Campbell BH, Bohanon J, 
Jaffar AT, Drane W, Sjoberg PA, Mazurek GH. 
Variability of the QuantiFERON(R)-TB Gold In-Tube 
test using automated and manual methods. PLoS 
One 2014 Jan 23; 9(1):e86721. 
 
Zetola NM, Modongo C, Moonan PK, Ncube R, 
Matlhagela K, Sepako E, Collman RG, Bisson GP. 
Clinical outcomes among persons with pulmonary 
tuberculosis disease caused by M. tuberculosis 
isolates with phenotypic DST heterogeneity. J Infect 







Paul Lawrence Grzybowski has joined the Applied 
Research Team of the Laboratory Branch as an Oak 
Ridge Institute for Science and Education (ORISE) 
Fellow. He will assist in the spoligotyping of M. 
tuberculosis (using the Ion Torrent instrument). Paul 
received his B.S. degree in chemistry from the 
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Georgia Institute of Technology in 2012. During his 
time at Georgia Tech, he participated in research 
exploring new reaction mechanisms using indium 
catalysts to offer an efficient and cost effective way to 
synthesize large heteroaromatic compounds. These 
mechanisms were then used in the synthesis of 
flinderole C, a natural antimalarial product. Paul is 
interested in merging drug design and development 
with microbiology to find new methods to improve 
public health. 
Kartee Johnson has joined the Applied Research 
Team of the Laboratory Branch as an Oak Ridge 
Institute for Science and Education (ORISE) Fellow. 
Kartee will be helping evaluate the effect of the 
enzymatic activity of pyrazinamide (PZA) mutations in 
M. tuberculosis. This work will contribute to a better 
approach for determining drug resistance through 
conventional and molecular methods, important in 
clinical practice and clinical trials of new drugs. He 
received his B.S. degree in biology with a minor in 
French from Berry College, Rome, Georgia, in 2013. 
During his time at Berry, he participated in research 
projects including analyzing the spatial and temporal 
patterns of sexual dimorphism and sex ratio on 
Lindera benzoin (also known as spicebush), which 
was recently published in the Journal of the Torrey 
Botanical Society; and also examining the activities of 
a specific vaccine in mice. 
Christine Ho, MD, MPH, joined the Surveillance, 
Epidemiology, and Outbreak Investigations Branch 
as the Team Lead of the Epidemiology Team on 
February 3, 2014. Christine has a BA in Biophysics 
and Art from the University of California, Berkeley, 
which explains everything. She has an MPH in 
epidemiology, and she received her MD in 1993 and 
completed her residency at the University of 
California, San Francisco. She is Board Certified in 
Internal Medicine. 
Christine was an Associate Professor of Medicine at 
the University of California, San Francisco, before 
joining CDC as a field Medical Officer in San 
Francisco, where she supervised contact 
investigations and led the development of new 
policies and procedures to improve completion rates 
for contact evaluations. While in San Francisco, 
Christine was the Co-Principal Investigator there for 
the Tuberculosis Epidemiologic Studies Consortium. 
Christine moved to Atlanta in 2012 as a Medical 
Officer in the Field Services and Evaluation Branch. 
In that role, she has led the project on Post-marketing 
Surveillance of 12-Dose Isoniazid and Rifapentine, 
has co-chaired the DTBE workgroup on the 
Affordable Care Act, has been the CDC liaison for the 
federal corrections healthcare council, and has 
participated as a "Think Tank" member. In her new 
job with SEOIB, Christine will lead TBESC-II at a 
crucial juncture as the consortium decides its future 
direction in understanding and improving screening 
for latent TB infection. 
Bryan Kim has left DTBE to take a position in the 
Division of Global HIV/AIDS. His last day in IRPB 
was March 21, and he started his new position in 
DGHA on March 23, 2014. In his new position, Bryan 
will serve as the Deputy Director for CDC's DGHA 
program in Lesotho based in Maseru. He will serve 
as the principal management and administrative 
person for all CDC/DGHA activities in country. Bryan 
will be responsible for formulating the program 
budget and presenting and defending resource 
requirements needed to carry out the office's long-
term goals and objectives. He will oversee the overall 
planning, directing, and execution of several 
programmatic activities for the office. He will also be 
responsible for providing program and operational 
support to Lesotho's President's Emergency Plan for 
AIDS Relief (PEPFAR) activities. 
As DTBE continues to increase its TB activities in 
Lesotho, Bryan will continue to provide in-country 
administrative and technical support to implement 
these activities. These activities include our ongoing 
TB drug resistance survey, and potential support to 
future Global Fund MDR TB technical assistance and 
TB/HIV related projects in Lesotho. 
Bryan has been with DTBE/IRPB for 10 years, most 
recently serving as the Deputy Branch Chief for 
IRPB. Although we are sad about Bryan leaving the 
Branch and the Division, he will be in a key position 
to facilitate DTBE/IRPB's collaborative work in 
Lesotho and Southern Africa. Bryan has been 
interested in working overseas for several years and 
this is a wonderful opportunity for him. 
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Kathryn Koski is the winner of the January 
NCHHSTP Director’s Recognition Award. Kathryn 
receives this award in recognition of her planning, 
professional leadership, and exceptional coordination 
of four unprecedented events over the last 8 months. 
In May, DTBE began coordinating efforts to move 
from Corporate Square’s Building 11 to Building 12. 
Already underway at the time was DTBE’s response 
to the budget sequestration and planning for a 
potential government shutdown. To add another layer 
of complexity, the Division Director and Deputy 
Director had recently accepted long-term details. 
Throughout the last 8 months, it is remarkable that 
despite intense pressure, Kathryn never lost her 
composure or sense of humor, and remained calm, 
approachable, compassionate, and committed to 
public health. She’s been able to lead DTBE through 
a smooth office space transition, re-work the Division 
budget for sequestration, plan for the furlough, and 
serve as Acting Deputy Director without 
compromising her work ethic or jeopardizing the 
quality of her work. 
Bonnie Plikaytis is serving as acting chief for the 
Laboratory Branch until a new chief can be selected. 
Bonnie has 35 years of service as a microbiologist at 
CDC, 25 of which have been in the mycobacteriology 
laboratory. In 2007 she became the deputy for the 
Laboratory Branch. She is no stranger to the 
responsibilities of the branch chief position, having 
served as acting branch chief for 18 months from 
November 2008 until June 2010. During her previous 
time as acting chief, she laid the foundation for the 
current portfolio of branch activities including the 
molecular detection of drug resistance service, 
applied research on mechanisms of drug resistance, 
and systems research to strengthen laboratory 
capacity. We thank Bonnie for her willingness to 
serve while DTBE recruits a permanent Laboratory 
Branch Chief. 
Benjamin (Ben) Silk, PhD, Lieutenant Commander, 
U.S. Public Health Service, has joined the Molecular 
Epidemiology Activity in SEOIB, DTBE. Ben has over 
15 years of experience in surveillance, outbreak 
investigations, and applied research related to 
infectious diseases. He began his career as a Peace 
Corps Volunteer in El Salvador. Since then, he has 
worked at the local and state levels for health 
departments in California, Georgia, and Louisiana. 
Ben completed his doctoral studies in epidemiology 
at Emory University's Rollins School of Public Health. 
In 2008, he joined CDC as an Epidemic Intelligence 
Service (EIS) Officer with the Respiratory Diseases 
Branch in NCIRD. After EIS, Ben served as a subject 
matter expert on listeriosis with the Enteric Diseases 
Epidemiology Branch in DFWED. He is especially 
interested in invasive and bacterial diseases that 
affect vulnerable populations. 
David Temporado was presented with the Associate 
Director for Laboratory Science (ADLS) Quarterly 
Award on February 19, 2014, for his extraordinary 
contributions to NCHHSTP and to DTBE's Laboratory 
Branch. He successfully orchestrated the move of 
over 93,000 isolates of M. tuberculosis from the 
genotyping contract laboratories to CDC. 
For the past 10 years, DTBE has funded two contract 
laboratories, one in Michigan and one in California, to 
genotype one isolate of M. tuberculosis from each 
culture-confirmed case of TB. With the contracts 
expiring in September 2013, he made arrangements 
to purchase freezers for housing the isolates at CDC, 
and to transport the isolates from the contract 
laboratories to CDC. He coordinated the process, 
working closely with PGO, the CDC genotyping 
project officer, and the staff at the contract 
laboratories. This complex project consisted of 
acquiring equipment, specialized transport services, 
and replacement freezer racks. It also involved 
logistics to gain entry into the contract laboratories 
storing the isolates and coordination of personnel at 
each site to oversee the movement of the shipment. 
The arrangements took 9 months to complete, and 
the highly specialized delivery of 93,000 vials 
containing Biosafety Level 3 organisms maintained at 
-80°C arrived safely this January. These isolates are 
a valuable collection, as the genotyping information is 
linked to the surveillance data in the TB GIMS 
database, allowing for tracking of outbreaks and 
transmission of TB. 
Mr. Temporado's extraordinary efforts as project 
coordinator, his commitment to the task, and his 
tenacious attention to detail are all greatly 
appreciated and resulted in a successful mission. 
Because of Mr. Temporado's devotion to his job and 
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the Laboratory Branch, Dr. Edwin Ades was pleased 
to give him the recognition he deserves. 
The ADLS office recognizes NCHHSTP's laboratory 
scientists and staff by presenting the Quarterly 
NCHHSTP ADLS Recognition Award to an FTE, 
contractor, or fellow who has demonstrated 
outstanding work ethic and greatly contributed to the 
mission of his/her branch. 
The Tuberculosis Surveillance Quality Assurance 
Training Team members are the worthy recipients of 
the DTBE Director’s Quarterly Recognition Award for 
the second quarter of 2014.  Members of the team 
are Lilia Manangan, Cheryl Tryon, Elvin Magee, 
Sandy Price, Stacey Parker, Robert Pratt, Kai Young, 
Juliana Grant, Angela Starks, Beverly Metchock, 
Glenda Newell, Lori Armstrong, Rachel Yelk 
Woodruff, Carla Jeffries, Alstead Forbes, Derrick 
Felix, Ann Lanner, Amera Khan, Smita Ghosh, and 
Roque Miramontes. 
CDC’s transition to a web-based surveillance system 
created a need for a standardized quality assurance 
(QA) process to govern the collection and reporting of 
high-quality TB data. QA of surveillance data is 
paramount to surveillance programs, but no current 
internal or external model existed to describe the QA 
process. The team developed the first 
comprehensive national QA training program for TB 
surveillance data in the U.S., which standardized 
methodologies, skills, and tools. The team’s 
innovative efforts resulted in the development of the 
following: 
• The QA process focuses on the five QA 
components, which are case detection, data 
accuracy, data completeness, data timeliness, 
and data security and confidentiality. 
• The QA guide provides policies and procedures 
for conducting each of the QA components, as 
well as definitions, study questions, and 
examples of the QA tools. 
• The QA toolkit includes approximately 50 QA 
tools (i.e., tables, charts, graphs, processes, and 
templates) that were developed by staff from 
CDC and various jurisdictions. 
The QA training course focused on the QA process 
and five components. The course format included 
presentations from faculty (DTBE subject matter 
experts) with interactive activities. Participants 
completed exercises to apply the content to realistic 
situations, shared experiences and answered 
questions, and described how they conduct QA in 
their own jurisdictions and overcome challenges.  
Despite challenges imposed by various TB 
surveillance systems, economic constraints, and new 
diagnostic technologies, the team developed QA 
strategies with innovation and collaboration. 
Congratulations to the Tuberculosis Surveillance 
Quality Assurance Training Team for this well-
deserved honor.  
§ 
In Memoriam 
Charles P. Felton, M.D., 87, of Palisades, NY, died 
January 16, 2014. Charles, or Chuck, was born May 
6, 1926, in New Orleans, LA. He graduated from St. 
Augustine's Seminary in 1944, received a B.S. 
degree from Xavier University in 1949, and earned a 
Doctorate of Medicine from the University of Geneva, 
Switzerland, in 1956. He and Hiroko ("Susie") Felton 
married in 1958, building a home together in 
Palisades, NY, where they raised their three sons. 
 
Chuck was an esteemed Clinical Professor Emeritus 
of Medicine at Columbia University's College of 
Physicians and Surgeons and Chief of Pulmonary 
Medicine at Harlem Hospital Center. He spent his 
career fighting TB in America's urban communities, 
Haiti, and beyond. He traveled extensively around the 
world, but loved most to spend time at home with 
family, gardening and cultivating his bonsai. 
 
In lieu of flowers, the family is requesting that 
donations be made to the American Lung Association 
in New York or to the Charles P. Felton National 
Tuberculosis Clinic at Harlem Hospital Center. 
John “Gus” Caras, 85, passed away on January 28, 
2014, after a long battle with Alzheimer's Disease. 
Born in Greece on January 20, 1929, he came to the 
United States in 1947 at the age of 18. He served in 
the U.S. Army for 2 years at Fort Bragg in North 
Carolina. Following his military service, he attended 
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the Georgia Institute of Technology in Atlanta, where 
in 1958 he earned a bachelor's degree in Chemical 
Engineering and in 1967 earned a master's degree in 
Information and Computer Science. 
He began his career as a chemist with Thiokol 
Corporation in Huntsville, Alabama, and also worked 
for the Army Missile Command designing rocket 
propellants. In 1966 he moved to Atlanta with his 
family and joined CDC’s Division of TB Control, 
where he worked as a statistician for many years, 
retiring in 1992. He worked with Dr. Dixie Snider and 
later with Dr. Rick O’Brien. Among other things, Gus 
was a co-author with Dixie Snider and Don Kopanoff 
on the investigations related to INH hepatitis that are 
often cited. 
Gus was very proud of his Greek heritage, and was a 
lifelong member of the Greek Orthodox Church. He 
enjoyed spending time with his grandchildren, 
traveling, and watching Georgia Tech football. In lieu 
of flowers, donations may be made to the 
Annunciation Greek Orthodox Cathedral, 2500 
Clairmont Road, N.E.; Atlanta, GA 30329.  
CALENDAR OF EVENTS 





May 16–21, 2014 
ATS International Conference 
San Diego, CA 
American Thoracic Society  
 
June 1–4, 2014 
APHL Annual Meeting and 8th Government 
Environmental Laboratory Conference 
Little Rock, AR 
Association of Public Health Laboratories (APHL) 
 
June 3–4, 2014 




Sept. 7–9, 2014 
American College of Epidemiology (ACE) Meeting 
Silver Spring, MD 
American College of Epidemiology  
 
Sept. 16–18, 2014 





Oct. 28–Nov. 1, 2014 
45th Union World Conference on Lung Health 
Barcelona, Spain 
International Union Against Tuberculosis and Lung 
Disease  
 
Nov. 15–19, 2014 
142nd APHA Annual Meeting 
New Orleans, LA 
American Public Health Association (APHA)  
